Introduction
We routinely manage safety pharmacology studies, generally as part of “first-in-man” non-clinical programmes. These studies are not conducted in-house but are sub-contracted to a partner organisation with specialist experience in this area. Our preferred partner is CERB.
CERB has more than 100 models/methods established for the assessment of primary and secondary functions or safety of new drug candidates. http://www.cerb.fr/index.html
-
Primary pharmacology
-
Proof of concept
-
Disease models
-
Early safety pharmacology
-
ICH S7A Core battery